Title and Organization:
Dena Grayson is a biotechnology executive with strong leadership skills, clear strategic vision, proven drug development expertise, and successful fundraising and business development experience. She currently serves as President of MedExpert Consulting, Inc. Dena played a key role in raising over $120 million for several biotechnology companies. She helped lead the development of Amgen’s recently approved cholesterol drug, Repatha (evolocumab). She has developed therapeutics in hematology, oncology, infectious diseases / biodefense, nephrology, cardiology, metabolism, inflammation, neurology, and several orphan indications. Dena's medical research has been published in prominent scientific journals, such as Nature, and featured in the New York Times. She is a 2006 Henry Crown Fellow of the Aspen Institute and a member of the Aspen Global Leadership Network.